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Abstract: Gynecologic cancers are among the leading causes of death worldwide, ovarian cancer
being the one with the highest mortality rate. Olaparib is a targeted therapy used in patients
presenting mutations in BRCA1 and BRCA2 genes. The aim of this study was to describe BRCA1
and BRCA2 gene variants in Mexican patients with ovarian cancer. Sequencing of BRCA1 and
BRCA2 genes from tumors of 50 Mexican patients with ovarian cancer was made in a retrospective,
non-randomized, and exploratory study. We found genetic variants in 48 of 50 cases. A total of
76 polymorphic variants were found in BRCA1, of which 50 (66%) had not been previously reported.
Furthermore, 104 polymorphic variants were found in BRCA2, of which 63 (60%) had not been
reported previously. Of these polymorphisms, 5/76 (6.6%) and 4/104 (3.8%) were classified as
pathogenic in BRCA1 and BRCA2, respectively. We have described the genetic variants in BRCA1
and BRCA2 of tumors from Northeast Mexican patients with sporadic ovarian cancers. Our results
showed that the use of genetic testing helps recognize patients that carry pathogenic variants which
could be beneficial for personalized medicine treatments.
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1. Introduction
Gynecologic cancers are among the leading causes of death worldwide, ovarian cancer being the
one with the highest mortality rate, registering an incidence of 238,719 patients and 151,905 deaths
in 2012, as reported by the World Health Organization (WHO) [1]. In the same year, Mexico had
3277 cases and 2105 people perished due to this disease. The trend for Mexico has been the same
for the last 40 years. Compared with developing countries, Mexico has a low rate of cases [2].
Unfortunately, WHO has not updated the data on incidence and mortality rates for ovarian cancer
in its electronic website. Recently, the estimated new cases and deaths of ovarian cancer for the
United States of America for 2018: 22,240 and 14,070, respectively, were published [3].
Mortality is attributed to the absence of a sensitive and specific test that allows diagnosis in early
stages [4,5]. To date, the American Cancer Society recommends screening with pelvic exploration,
transvaginal ultrasound (TVUS), and detection of CA-125 for diagnosis of ovarian cancer, but this is
possible only with biopsy of ovarian tissues [6]. Extensive studies have been conducted to determine
the clinical utility of CA-125 and TVUS, however, results indicate a poor utility in reducing the
incidence and mortality of ovarian cancer [7,8]. CA-125 is not a specific biomarker for ovarian cancer,
it can be increased in other types of cancer and other specific non-malignant women’s conditions,
such as pregnancy, pelvic inflammatory disease, and infectious disease [9–11]. High levels of CA-125
are detected in up to 80% of ovarian cancer patients with advanced disease and up to 60% in early
stages. Moreover, its detection for clinical outcome is not recommended [5,12].
Beyond a specific diagnostic test, the lack of success for chemotherapy strategies plays a key
role in ovarian cancer mortality. Recently, the Food and Drug Administration (FDA) approved a
targeted therapy with the use of olaparib (Lynparza, AstraZeneca) that shows benefits in patients who
carry mutations in any genes of homologous recombination, but mainly in BRCA1 and BRCA2 [13,14].
Olaparib inhibits the single strand DNA damage repair pathway through poly-ADP ribose polymerase
(PARP) [15–17]. The use of this drug has demonstrated better objective response rates in platinum
sensitivity patients with BRCA1 and BRCA2 mutations in phase II clinical trials and retrospective
multicenter studies [18,19].
The refinement and cost reduction in Next Generation Sequencing technologies have allowed the
expansion of genetic knowledge of human diseases [20,21]. Next Generation Sequencing applications
have revealed the genomic landscape of the ovarian tumors types [22]. In this way, the mutations in
the BRCA genes and their dysfunctions have helped drive clinical trials for olaparib administration in
ovarian cancer patients [23].
Genomic variation findings of tumor driver genes are making it possible to personalize the
treatment of cancer patients. Personalized cancer treatment includes early diagnosis, targeted therapy,
monitoring response to treatment, tracking resistance, and prediction of disease-free survival.
More recently, it has benefited from the isolation and analyses of circulating tumor DNA and
Circulating Tumor Cells from plasma (liquid biopsies) [24–26].
The aim of this study was to describe genetic variants in the BRCA1 and BRCA2 genes in tumors
from Northeast Mexican patients with sporadic ovarian cancer and to detect the percentage of potential
eligible patients for future olaparib clinical trials.
2. Materials and Methods
2.1. Study Population and DNA Extraction
We conducted a retrospective, non-randomized, and exploratory study to search genetic variants
in BRCA genes. The research protocol was approved by the Ethics Committee in Research of the
Hospital Universitario at the Universidad Autonoma de Nuevo Leon (HU-UANL), with the registration
number Bl13-005.
We collected cases from the Pathology Departments of public and private hospitals that
participated in the study. Pathologists selected tumors from paraffin embedded tissues blocks for the
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identification of tumor cellularity of >80%. We ensured quality by avoiding areas of inflammation and
necrosis. The patients have sporadic ovarian cancer.
Tumor samples were obtained from 10 mg tissues and DNA was extracted using the AllPrep
DNA/RNA FFPE kit (Qiagen, Hilden, Germany). DNA concentrations and quality (ratio 260 nm/280 nm,
value ≥ 1.8) were evaluated by the NanoDrop 8000 Spectrophotometer (Thermo Scientific, Waltham,
MA, USA).
2.2. DNA Sequencing
Complete sequencing of the exons of BRCA1 and BRCA2 genes was performed in the Ion
Torrent Personal Genome Machine (PGM) Sequencer (Thermo Fisher Scientific, Waltham, MA, USA).
Sequence reads were mapped to the hg19 reference genome and used to generate BAM files; variants were
predicted using the both Torrent Suit Variant Caller (TSVC, Thermo Fisher Scientific, Waltham, MA, USA)
and the Genome Analysis Toolkit (GATK, Intel Corporation, Santa Clara, CA, USA).
The sequencing process started with 30 ng of DNA, which was processed according to the standard
protocol Multiplex Ion AmpliSeq BRCA1 and BRCA2 Panel (Life Technologies, Carlsbad, CA, USA).
The panel amplifies 167 amplicons that cover about 16.3 kb and result in coverage between 98–100%
of the coding regions of both genes. The libraries were designed according to the manufacturer by
the platform Ion AmpliSeq Library Preparation Protocol (Life Technologies, Carlsbad, CA, USA).
Each sample was labeled individually and added to the emulsion and subsequently sequenced using
a P1 chip. Each run of that protocol produced about 10 Gb of information and each sample had an
average depth of 500X [27].
2.3. Variant Calling, Filtering, and Annotation
Variants passing quality control and filtering were visually confirmed using the Integrative
Genomics Viewer (IGV) [28]. Rare variants (with a reported frequency <1% or absent from the
1000 Genomes Project and from the Exome Aggregation Consortium (ExAC) populations) were
examined as potential pathogenic mutations and annotated using Clininical Variation database (http:
//www.ncbi.nlm.nih.gov/clinvar). For missense variants, predictions of pathogenicity were generated
using Align-GVGD (http://agvgd.iarc.fr/).
3. Results
We included 50 tumors with a mean age of 51 years; the range was 33–86 years. The histological
tumor subtypes were distributed as follows: 10 high-serous grade (20%), 13 endometrioid (26%),
7 papillary, 6 mucinous (13%), 1 low-serous grade (2%), 10 clear cell (20%), 1 transitional cell (2%),
1 dysgerminoma (2%), and 1 borderline (2%).
We identified, in 48 of 50 (96%) cases, 76 polymorphic variants in BRCA1 of which 26 (34%) had
been previously reported. In BRCA2, we found 104 polymorphic variants of which 41 (39.4%) had also
been reported previously, these variants are showed in Figure 1. The rest of the BRCA1 and BRCA2
variants found (66% and 60% respectively) had not been previously reported. Our samples have an
average coverage of 650X.
We found pathogenic variants in BRCA1 and BRCA2, 5/76 (6.6%) and 4/104 (3.8%), respectively.
Table 1 shows pathogenic variants found in this study: 22% of variants were missense mutations,
55% nonsense, 11% intronic, 11% frameshift variants and 1% of deletions.
For samples with pathogenic variants, the histological subtype and age at diagnosis are shown
in Table S1. The sample from patient 2 had a mixture of histological types: 90% high-grade serous
carcinoma and 10% clear cell carcinoma; the sample from patient 13 was related to an early age of
diagnosis (33 years old) with a histological type of low-grade serous carcinoma.
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Table 1. Pathogenic variants in BRCA1 and BRCA2 in Mexican ovarian cancer patients.
Gene Variants HGVS Amino Acid Change Genomic Location (GHCh38) Type
BRCA1
rs80356862 4868C>G A1623G Chr17:43071046 Missense variant
rs80358027 c.4357+1G>A IVS13+1G>A Chr17:43082403 Splice donor variant
rs80357260 c.4183C>T Q1395* Chr17:43090946 Nonsense variant
rs80357284 c.5346G>A W1782* Chr17:43049181 Nonsense variant
rs80357219 c.5345G>A W1782* Chr17:43049182 Nonsense variant
BRCA2
rs80359082 c.8377G>A G2793R Chr13:32370447 Missense variant
rs80358557 c.3109C>T Q1037* Chr13:32337464 Nonsense variant
rs80359775 c.9699_9702delTATG C3233Wfs Chr13:32398212 - 32398215 Frameshift variant
rs80358981 c.7558C>T R2520* Chr13:32356550 Nonsense variant
*: Codon stop gain.
4. Discussion
In Mexico, the Federal Health Secretary’s prevention campaign directed for women focuses on
breast and cervical cancers. Ovarian cancer is an urgent health problem for screening campaigns,
taking advantage of new genomic technologies, such as Next Generation Sequencing methods, can help
with better diagnoses and suggest new treatment approaches, such as personalized medicine [29–31].
The information reviewed in the Clinical Variation database showed that the BRCA1 and BRCA2
pathogenic variants found in our study have been reported in patients with breast cancer or ovarian
cancer patients [32]. It is important to identify BRCA1 and BRCA2 pathogenic variants in ovarian
cancer because they are therapeutic targets for olaparib therapy.
We can see similarities in the BRCA1 variants because rs1060915 (40%), rs16941 (40%),
rs16940 (40%), rs1799966 (40%), rs16942 (36%), rs799917 (44%), rs1799949 (38%), rs3765640 (30%)
are mostly present in samples with endometrioid and clear cell types. An unusual finding was the
detection of 26 variants (four of them pathogenic) in endometrioid sample 36 (Figure 1 and Table S1).
All histological types presented similarities in BRCA2 with variants rs144848 (100%), rs206075 (100%),
rs206076 (97.9%), rs169547 (95.8%), rs953426 (70.8%). Mutations in BRCA genes are rarely detected in
the endometrioid histological type according to the COSMIC database [33]. The majority of mutations,
variants, and epigenetic modifications in BRCA1 are reported in the high-grade serous carcinoma
samples [22].
The standard treatment for ovarian cancer is surgery and/or chemotherapy with platinum or
taxanes, depending of the tumor phase; however, treatment with inhibitory PARPs can be improved
if the genetic test reveals BRCA mutations. Patients can expect a better therapeutic response if
they are platinum sensitive and are treated with combination therapy with inhibitory PARPs [34,35].
Patients who are carriers of BRCA1 mutations have a better prognosis than those with epigenetic
events [22].
Gelmon (2011) directed a phase 2, multicenter, open label, non-randomized study with
65 high-grade serous ovarian cancer patients: 17 were BRCA mutation carriers and only 7 patients
(41%) had a positive response to treatment. On the other hand, 11 of 46 non-BRCA mutation
carriers responded to olaparib [36]. Another study done by Ledermann (2012) included 265 patients
(two groups: treatment and placebo). The treatment group with 136 patients had a complete objective
response (criteria defined by Response Evaluation Criteria in Solid Tumors, RECIST) in 57 cases
(41.9%). In this study, 25 cases (18.4%) were BRCA1 mutation carriers and 6 cases had BRCA2 mutations
(4.4%) [37].
Compared with a previous Mexican study of breast/ovarian hereditary cancer patients, we found
six variants in common between the studies, all of them benign. These results are shown in Figure 2 [38].
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Figure 3. Mutations found in BRCA genes. Amino acid changes for the pathogenic variants are shown.
Boxes correspond to the variants that coincide with those reported by Vaca-Paniagua [38].
Villarreal-Garza (2014) ed the clinical significance of BRCA mutations in ovarian and breast
cancer patients with hereditary cancer history. They found BRCA mutations i 26 of 98 ovarian
cancer patients (28%), also reporting the Mexica founder mutati n BRCA1 ex9-12del in 35% of their
patients rom c ntral Mexico [39]. In comparison, we found pathogenic variants n BRCA genes in
12% f sele ted patients. This percentage is important because t corresponds to patien s with sp radic
cancer and shows th importance of molecular screenings in all patients for better diagnosis and
therapy strategies.
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Another important aspect to highlight is the difference in the molecular test for screening the
genetic variants in the BRCA genes. For example, we used Multiplex Ion AmpliSeq BRCA1 and BRCA2
Panel that includes primers for the entire coding region, whilst Villarreal-Garza and colleagues used
HISPANEL for Sequenom MassARRAY (Sequenom Inc., San Diego, CA, USA) and end point PCR for
BRCA1 ex9-12del mutation. Nevertheless, the founder mutation BRCA1 ex9-12del was absent in our
study likely because we have samples from sporadic cancer patients from the Northeast of Mexico,
in comparison with other studies that include patients with hereditary history of cancer and are from
central Mexico (Mexico City and Puebla State), the region of origin of this founder mutation [39–41].
Additionally, our methodology is not optimal for searching ex9-12del of BRCA1 because this is a large
rearrangement and our samples are from FFPE tissues with degraded DNA.
Mutation screenings in druggable driver genes are of great value for medical treatment decisions
in over 50% of ovarian cancer patients. For example, there are therapies for patients that carry
mutations in BRCA (olaparib), NF1 (temsirolimus), PI3K/RAS (sorafenib), or that exhibit HER2 over
expression (trastuzumab) [42]. The next step in the implementation of personalized medicine of
ovarian cancer is the search for these genetic alterations with Next Generation Sequencing, real time
PCR, droplet digital PCR, or Sanger Sequencing through the use of liquid biopsies from blood, urine,
or liquid Pap smears.
The Mexican population is genetically diverse, consisting of peoples of Amerindian, European,
African and Asian descent and detailed ancestry studies have been described by other Mexican
research groups [43]. We have reported the diversity of polymorphism frequencies for the CYP2D6,
CYP3A5, CYP2C8, and IL-10 genes in breast cancer patients from Mexico and Spain and classified
them by metabolic activity for chemotherapy but no specific function has been described for these
polimorphisms [44]. Previously, we identified polymorphisms associated with the metabolism of
atorvastatin with the aim of finding pharmacokinetic biomarkers in the Mexican population [45].
Our study reports for the first time the genetic diversity of BRCA1and BRCA2 genes in tumors
from Northeast Mexican ovarian cancer patients. In addition, we report pathogenic variants in these
genes according to the ClinVar database (accessed May, 2018).
This work raises the need to implement molecular genetic testing with high specificity, sensitivity,
and low cost for all ovarian cancer patients. Test results may help oncologists offer more precise
molecular diagnosis and better personalized therapies. In this case, 12% of patients could be candidates
for olaparib therapy.
Dean et al. showed the importance of performing screening of genetic variants along BRCA
genes in Hispanic populations. These populations have limited economic resources to access genomic
medicine for better prognosis and treatment of ovarian cancer [27].
Comprehensive studies that include high-quality samples from biobanks, complete clinical
records, and better bioinformatics analyses are very important to identify key factors for the diagnosis,
treatment, and follow-up of the therapeutic response of ovarian cancer patients [46,47].
5. Conclusions
We have described genetic variants in BRCA1 and BRCA2 from tumors of Northeast Mexican
patients with sporadic ovarian cancer. Our results showed that the use of genetic testing helps identify
patients that carry pathogenic variants that could beneficial for personalized medicine treatment.
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